United-Guardian Reports Higher Third Quarter Earnings

Third-quarter operating income rose to $1,108,928 from $215,072 as sales increased across all three reported product categories.

Rhea-AI Summary

United-Guardian (NASDAQ:UG) reported third-quarter 2026 net income of $930,912, with sales growth across pharmaceuticals, cosmetic ingredients and medical lubricants. Net income rose 247% from $268,441, while basic and diluted earnings per share increased to $0.20 from $0.06. Net sales rose 54% to $3,494,780 from $2,264,261.

For the nine months ended September 30, 2026, sales increased 25% to $9,475,269, and net income rose 70% to $2,478,393; earnings per share reached $0.54 versus $0.32. Third-quarter pharmaceutical sales grew 29%, cosmetic ingredient sales increased 187%, and medical lubricant sales rose 20%, each compared with 2025. Nine-month earnings included $339,493 in settlement income. United-Guardian plans to launch a personal care product in early 2027. Costs increased in both reporting periods, while investment income declined.

13 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointThird-quarter net sales increased 54% to $3,494,780 from $2,264,261 in 2025.
• Moderate pointThird-quarter net income rose 247% to $930,912 from $268,441; earnings per share increased to $0.20 from $0.06.
• Moderate pointThird-quarter operating income increased to $1,108,928 from $215,072 in 2025.
• Moderate pointNine-month settlement income of $339,493 compared with none in 2025. 1.1% of market cap
• Minor pointNine-month net sales increased 25% to $9,475,269 from $7,583,613 in 2025.

8 minor points

• Minor pointNine-month net income rose 70% to $2,478,393 from $1,456,162; earnings per share increased to $0.54 from $0.32.
• Minor pointNine-month operating income increased to $2,505,502 from $1,521,447 in 2025.
• Minor pointPharmaceutical sales grew 29% year over year in the third quarter, driven primarily by Renacidin.
• Minor pointCosmetic ingredient sales increased 187% year over year in the third quarter, led by increased Ashland Specialty Ingredients purchases.
• Minor pointMedical lubricant sales grew 20% year over year in the third quarter, reflecting increased purchases from an Indian customer.
• Minor pointNine-month gain on sale of an asset of $8,310 compared with none in 2025.
• Minor point. Forward-looking: it has not happened yet and may not happen.Personal care product in late-stage development is planned for launch in early 2027.
• Minor pointRenacidin marketing efforts are being evaluated to increase awareness among healthcare professionals.

Negative

• Moderate pointThird-quarter cost of sales rose to $1,619,479 from $1,311,192; nine-month costs reached $4,629,733 versus $3,775,122.
• Minor pointThird-quarter operating expenses rose to $644,539 from $620,893; nine-month expenses reached $1,978,784 versus $1,947,678.
• Minor pointThird-quarter research and development expense rose to $121,834 from $117,104; nine-month expense reached $361,250 versus $339,366.
• Minor pointThird-quarter investment income declined to $72,556 from $75,165; nine-month income fell to $212,815 from $230,425.
• Minor pointThird-quarter marketable securities recorded a $7,916 loss versus a $36,238 gain in 2025.

2 minor points

• Minor pointNine-month marketable securities gains declined to $58,191 from $73,164 in 2025.
• Minor pointThird-quarter income tax provision rose to $242,656 from $58,034; nine-month provision reached $645,918 versus $368,874.

News Explained

Third-quarter income from operations rose to $1,108,928 from $215,072, while total other income fell to $64,640 from $111,403; the reported earnings increase accompanied stronger operating income, not higher other income.

Key Figures

Third-quarter net sales: $3,494,780 vs. $2,264,261 (+54%) Third-quarter net income: $930,912 vs. $268,441 (+247%) Third-quarter earnings per share: $0.20 vs. $0.06 +2 more

Third-quarter net sales

$3,494,780 vs. $2,264,261 (+54%)

Third quarter 2026 vs. 2025

Third-quarter net income

$930,912 vs. $268,441 (+247%)

Third quarter 2026 vs. 2025

Third-quarter earnings per share

$0.20 vs. $0.06

Third quarter 2026 vs. 2025

Nine-month net sales

$9,475,269 vs. $7,583,613 (+25%)

Nine months ended September 30, 2026 vs. 2025

Nine-month net income

$2,478,393 vs. $1,456,162 (+70%)

Nine months ended September 30, 2026 vs. 2025

Historical Context

1 past event · Latest: Aug 07

1 event

1. Aug 07

   Quarterly earnings

   24h Move

   +0.8%

   Q2 sales and net income rose, providing the preceding quarterly results for comparison with Q3.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

formulary coverage, weighted average shares, marketable securities

3 terms

formulary coverage medical

"the expanded formulary coverage we achieved earlier this year"

Formulary coverage is the list of prescription drugs a health plan or insurer agrees to pay for and the terms (such as copay levels or prior authorization) under which they will pay. It matters to investors because placement and tiering on a formulary strongly influence a drug’s sales, pricing power and adoption—similar to a product being stocked on prime store shelves versus a backroom shelf, which affects how much and how easily consumers can buy it.

weighted average shares financial

"Weighted average shares (Basic and Diluted)"

Weighted average shares is the average number of a company’s shares outstanding over a reporting period, calculated by giving each share count the proportion of time it was in effect—so shares issued or bought back partway through the period count only for the time they existed. Investors use it to turn totals like profit into per-share measures (e.g., earnings per share), making performance comparable over time; think of it like averaging daily car use to report a fair miles-per-day figure.

marketable securities financial

"Net (loss) gain on marketable securities"

Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAUPPAUGE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and first nine months of 2026. Third quarter net sales increased by 54% from $2,264,261 in 2025 to $3,494,780 in 2026, with net income increasing 247% from $268,441 ($0.06 per share) to $930,912 ($0.20 per share). Net sales for the nine-month period ended September 30^th increased by 25% from $7,583,613 in 2025 to $9,475,269 in 2026, and net income increased by 70% from $1,456,162 ($0.32 per share) to $2,478,393 ($0.54 per share).

Donna Vigilante, President of United-Guardian, stated, “I am very excited to report that our third quarter was exceptionally strong, with pharmaceuticals, personal care and medical lubricants all posting sales increases. Pharmaceutical sales grew 29% compared with the same period in 2025, driven primarily by Renacidin^®, our most important pharmaceutical product. The increase was partly attributable to the expanded formulary coverage we achieved earlier this year. In addition, cosmetic ingredient sales surged 187% over the same period in 2025, led by increased purchases from Ashland Specialty Ingredients (“ASI”), our largest marketing partner. Medical lubricants also grew 20% compared with the same period in 2025, reflecting increased purchases from one of our customers in India.”

“I am very pleased with our performance for the first nine months of 2026. Our growth initiatives have produced encouraging results, and we plan to continue building on this progress. In pharmaceuticals, we are in the process of determining which marketing efforts to deploy to increase awareness of Renacidin among healthcare professionals. In personal care, we have a new product in late-stage development that we plan to launch early next year. We are hopeful that our continued efforts will drive further growth and lead to increased sales.”

United-Guardian is a diversified life sciences and personal care ingredients company that develops, manufactures, and globally commercializes proprietary pharmaceuticals, medical lubricants, specialty cosmetic ingredients and consumer wellness products.

Contact:	Donna Vigilante
	(631) 273-0900
	dvigilante@u-g.com

^{NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.}

Financial Results for the
Three and Nine Months Ended
September 30, 2026 and 2025
STATEMENTS OF INCOME
(unaudited)
		THREE MONTHS ENDED SEPTEMBER 30,					NINE MONTHS ENDED SEPTEMBER 30,
		2026			2025			2026			2025
Net sales	$	3,494,780		$	2,264,261		$	9,475,269		$	7,583,613
Costs and expenses:
Cost of sales		1,619,479			1,311,192			4,629,733			3,775,122
Operating expenses		644,539			620,893			1,978,784			1,947,678
Research and development expense		121,834			117,104			361,250			339,366
Total costs and expenses		2,385,852			2,049,189			6,969,767			6,062,166
Income from operations		1,108,928			215,072			2,505,502			1,521,447
Other Income:
Investment income		72,556			75,165			212,815			230,425
Net (loss) gain on marketable securities		(7,916	)		36,238			58,191			73,164
Settlement income		---			---			339,493			---
Gain on sale of asset		---			---			8,310			---
Total other income		64,640			111,403			618,809			303,589
Income before provision for income taxes		1,173,568			326,475			3,124,311			1,825,036
Provision for income taxes		242,656			58,034			645,918			368,874
Net income	$	930,912		$	268,441		$	2,478,393		$	1,456,162
Earnings per common share (Basic and Diluted)	$	0.20		$	0.06		$	0.54		$	0.32
Weighted average shares (Basic and Diluted)		4,594,319			4,594,319			4,594,319			4,594,319

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were United-Guardian's third-quarter 2026 earnings and sales?

United-Guardian reported net income of $930,912, or $0.20 per basic and diluted share, on sales of $3,494,780. Compared with the third quarter of 2025, net income increased 247% and sales increased 54%.

What drove United-Guardian's third-quarter 2026 pharmaceutical sales growth?

Renacidin primarily drove the 29% year-over-year increase in pharmaceutical sales. The company attributed part of the increase to expanded formulary coverage achieved earlier in 2026.